Chronic pelvic pain is a common condition in women and rates of consultation in general practice are similar to those for asthma and migraine. USA and UK population-based studies, together with data from UK hospital settings, demonstrate a substantial impact of chronic pelvic pain on health related quality of life. In this review we examine the current evidence for treatment of the condition, focusing on randomised controlled trials and including some insights from studies of women with dysmenorrhoea.
Introduction
Chronic pelvic pain (CPP) is a common condition in women of reproductive age. Current data from the USA and UK suggest that it occurs in 14-24% of women aged between 18-50 years.
1,2 The differences in estimated prevalence may be due to the design and type of study performed; for example, the use of different definitions of the condition. Most research has, however, used six months as the duration of symptoms to identify CPP. It is a common condition at the population level. Further work has indicated that rates of consultation for CPP in general practice are similar to those for asthma and migraine; it is important to note that consulting rates are actually higher in the postmenopausal age group, which has not been studied as yet at the population level. 2 The USA and UK population-based studies, together with data from UK hospital settings, demonstrate a substantial impact of CPP on health related quality of life.
Typical laparoscopic findings in women investigated for CPP are, in increasing order of frequency: adhesions (24%), endometriosis (33%), and 'no pathology' (35%). 3 Patterns of symptoms and received diagnosis in the population-based studies cited above suggest a broad pattern of pathophysiology, with urinary (31%) and gastrointestinal (37%) problems being more common than specifically gynaecological (20%) problems. The spectrum of symptoms and diagnoses reported by these women no doubt reflects the populations studied, the limited diagnostic scope of conventional clinical methods and the different approaches to the management of the condition in the community as opposed to hospital or tertiary centres. More interestingly, up to a third of women with CPP do not consult a physician and of those who do, about 60% will not be referred on to tertiary centres. We do not yet fully understand what precipitates care seeking in women with CPP. It is possible that those women with the condition who do not seek care have less disruptive symptoms, as indicated by better scores for health related quality of life, but there is still a burden of physical and functional impairment among this group.
Pathology such as adhesions or endometriosis may not correlate with the site or severity of pain. This discrepancy can be explained in part by the complex neurophysiology of visceral sensation; in other words, sensation arising from the internal organs such as the uterus and ovaries. Normal body sensation can be perceived as painful because of alteration in processing of spinal cord and brain stimuli. 4 Thus, a significant number of women with CPP will not have a definite diagnosis. Explanations for CPP without pathology have included irritable bowel syndrome, which is often present in women referred to gynaecologists for investigation but missed without appropriate history taking. Pelvic congestion syndrome refers to dilated uterine and ovarian veins with reduced venous clearance and is present in a proportion of those in the reproductive age group with CPP. Endometriosis, pelvic inflammatory disease and isolated symptoms of dysmenorrhoea and dyspareunia are outside the scope of this review.
The current approaches to treatment of CPP include psychotherapy or counselling, reassurance via laparoscopy, hormonal manipulation using medroxyprogesterone acetate (MPA), surgery to interrupt nerve pathways such as presacral neurectomy and uterosacral nerve ablation, or hysterectomy with or without bilateral oophorectomy. Other novel approaches have included the use of photographic reinforcement after surgery as part of the counselling of women with CPP, use of magnetic field treatment and writing therapy. Although only preliminary data are available for these novel approaches, they merit consideration as treatment options are limited for this often challenging condition. While non-surgical approaches are less physically invasive they are more time consuming and may not always be acceptable to women who desire a rapid resolution of their problem. Surgery carries irreversible consequences and evidence on which to base advice to women about the outcomes is limited. Surgical trials in this area are difficult to conduct and are certainly few and far between.
Approaches to the treatment of CPP can also be considered in terms of single specialist versus multidisciplinary management. The latter comprises a team of specialists including a gynaecologist, a clinical psychologist, a physician with a special interest in pain management and specialist nurses to provide care and support ( Figure 1 ). Multidisciplinary management is a common approach to many chronic conditions such as asthma, diabetes and other conditions associated with chronic pain. This type of care is certainly slowly gaining recognition as relevant to the management of women with CPP. However, the limiting factor in setting up such services is often the cost and the availability of interested specialists. There are unresolved health service organisational questions about the appropriate setting of care and referral arrangements.
In this review we examine the current evidence for treatment of CPP, focusing on the randomised controlled trials that are available to date.
Randomised controlled trials of treatment for CPP There are 13 randomised controlled trials (Table 1) on the management of CPP. Interventions identified as the subject of randomised controlled trials for chronic pelvic pain were: progestogen (MPA) alone or in combination with psychotherapy; goserelin; sertraline; lofexidine hydrochloride; ultrasound scanning as an aid to counselling and reassurance; intravenous dihydroergotamine for acute exacerbations of chronic pelvic pain; and the use of a Polaroid photograph to assist in the woman's postoperative consultation. Other interventions also identified were: writing therapy to improve symptoms; static magnetic fields to improve pain; adhesiolysis via laparoscopy or laparotomy; and a multidisciplinary approach to investigation, including physiotherapy, psychology and attention to dietary and environmental factors. While hormonal therapy aims to achieve benefits in a non-specific manner by inhibiting ovarian activity (based on the observation that many women with CPP experience resolution at the time of the menopause), psychological approaches aim to enhance coping skills and reduce pain-associated distress. 6 showed an interaction between the effects of MPA and psychotherapy such that the group receiving both interventions did have a sustained benefit nine months post treatment. However, for reasons that are unclear, the 'placebo alone' group had an unexpectedly poor outcome, which makes the overall results more difficult to interpret.
In a study of Turkish women, venography scores, symptom and examination scores, mood and sexual function were improved to a greater extent one year after treatment with goserelin compared with progestogen.
7 Weighted mean differences No improvement in pain scores was seen in women taking sertraline compared with placebo. The SF-36 health perception subscale showed a small improvement in the sertraline arm, while the role-functioning emotional subscale showed a large fall in the sertraline arm. 8 Outcomes with lofexidine hydrochloride were no better than for placebo (OR for reduction in pain visual analogue scale 2.5, 95% CI 0.6-10.3). 9 Pain scores after dihydroergotamine were reduced up to 48 hours post injection.
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Multidisciplinary management
The use of a multidisciplinary approach led to a positive outcome in a self-rating scale (OR 4.15, 95% CI 1.91-8.99, n 5 106) and daily activity, but not in pain scores. 11 There are no other randomised controlled trials of treatment examining multidisciplinary care, mainly because individual treatment effects would be difficult to ascertain; thus, in general, trials for the treatment of pelvic pain are aimed at the examination of an individual medical or surgical treatment. The core elements of a multidisciplinary team will include a gynaecologist and physician with a special interest in pain management, a psychologist, a pain clinic nurse and a physiotherapist. Figure 1 shows a typical referral and management flow chart for women referred to the pain team at the Princess Anne Hospital in Southampton. women with CPP were included. Our conclusions should be interpreted with caution given that the pathophysiology of abdominal and pelvic pain may differ between men and women and the presence of gynaecological conditions such as endometriosis or pelvic inflammatory disease could, if left untreated, give rise to persistent pain. Thus, there is still uncertainty about the place of adhesiolysis among women presenting to gynaecologists and the conclusion of this review is that there is 'no evidence of benefit' rather than 'evidence of no benefit'. Two possible conclusions can be drawn: that further large trials of adhesiolysis recruiting gynaecology patients should be undertaken to provide the necessary level of evidence, or that, given the uncertainties about pathophysiology, clinical subgroups such as those with adhesions involving the ovaries, and the influence on outcomes of psychological and sociocultural variables, should be examined.
Researchers should also concentrate on careful observational studies including full psychological assessment of participants, laboratory characterisation of adhesion tissues and physiological investigation of intraperitoneal inflammatory and nociceptive processes. Other therapies
Static magnetic therapy
The effects of static magnetic therapy versus placebo 21 were analysed using the Wilcoxon rank sum test. The results showed no difference following two weeks of treatment. However, there were statistically significant differences with four weeks of treatment as assessed by the Pain Disability Index and the Clinical Global Impression Scale, but not the McGill Pain Questionnaire. For consistency, in this review we present the outcomes in terms of weighted mean differences, which show no significant differences. It is, however, important to note that in this study there was a high drop-out rate from the two week follow-up to the four week follow-up period (41% attrition rate).
Photographic reinforcement Photographic reinforcement after surgery does not appear to have any beneficial effect.
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Unfortunately, the intervention group had a trend for greater pain intensity compared with the controls, which may have confounded any possible beneficial effects of photographic reinforcement. Moreover, 233 women were entered into the trial, compared with the target of 450, so the final comparisons were somewhat different to those originally planned.
Writing therapy
The aim of this intervention is to allow patients to identify and express the thoughts and feelings associated with their pain as a means of reducing its impact. 
Conclusion
The information currently available about the treatment of women with chronic pelvic pain provides some support for the use of ultrasound scanning as an aid to counselling and reassurance, progestogen (MPA) or goserelin for pelvic congestion and (with the aim of improved function and self-rating) a multidisciplinary approach to assessment and treatment. Adhesiolysis is not shown to be of benefit other than in women with severe adhesions. Short-term results for PSN and LUNA seem to be similar, although PSN has better results in the long term. Selective serotonin reuptake inhibitors (SSRIs) have not been shown to be of benefit. Most of these conclusions are based on the outcome of single randomised trials and need replication. Writing therapy may have a place as part of a multidisciplinary programme.
Areas of future research
This review has shown that a limited range of interventions has been tested for the treatment of women with chronic pelvic pain, and that only single studies have been undertaken on most of these interventions, which greatly limits the available evidence on which clinical practice can be based. Further work is required to confirm the findings of existing studies. Given the prevalence and healthcare costs associated with chronic pelvic pain in women, randomised controlled trials of other medical, surgical and psychological interventions are required. As causation and treatment of chronic pelvic pain is often complex, the design of research studies needs adequately to integrate baseline psychological and clinical assessment. Studies currently needed include trials of radiological embolisation versus surgery for pelvic congestion, assessment of the value of neuropathic pain medications, and formal comparisons of outcomes from different packages of care.
